RE:RE:No update yet - why?!Interesting perspective. There is a need to distinguish who bought the licencing and global nature and structure of the agreement. Some critical details are not available to us like the royalty rate. In addition, if this goes into existing established product lines, then sales and royalties would be instant. This is unlike the R&F agreement where there was zero royalty, and only compensation for raw ingredients, and it was on a new product where they apparently diluted the heck out of our formula, as some poster eluded to.
I would say simply that this will depend how many products and the royalty rate assigned. There have been several financial scenarios posted here in the last year and half and even with $4-5 million a year over the next 15 years would translate into $60-75M in revenue - at least $40+ million of that is tax free if carryover losses are applied.